8-K: Y-mAbs Therapeutics Reports 10% Revenue Growth for Q2 2024, Expands DANYELZA Reach

Y-mAbs Therapeutics announced a 10% year-over-year increase in DANYELZA net product revenues for the second quarter of 2024, driven by international expansion.

Summary

• Y-mAbs Therapeutics reported a net product revenue of $22.8 million for the second quarter of 2024, a 10% increase compared to the same period in 2023.
• International DANYELZA revenues saw a significant 55% increase, reaching $7.6 million, due to growth in Western Europe and new launches in Brazil and Mexico.
• U.S. DANYELZA revenues decreased by 4% to $15.2 million, attributed to competition and ongoing clinical trials.
• The company's total net product revenue for the first six months of 2024 was $42.2 million, a 3% increase year-over-year.
• Y-mAbs has delivered DANYELZA to 65 centers across the U.S., adding two new centers in the second quarter of 2024.
• The company reported a net loss of $9.2 million for the quarter, or ($0.21) per share, and a net loss of $15.9 million for the first six months of 2024, or ($0.36) per share.
• The increased net loss was primarily due to a $3.8 million net charge related to legal settlements.
• Cash and cash equivalents stood at $77.8 million as of June 30, 2024, with a cash burn of $0.8 million in the first half of the year.
• Management anticipates the current cash runway will support operations into 2027.
• Full year 2024 total net revenue guidance is updated to between $87 million and $95 million, with operating expenses between $115 million and $120 million, and total annual cash burn between $15 million and $20 million.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to strong international revenue growth and a low cash burn, but tempered by a net loss and a decline in U.S. sales. The company's future outlook is promising, but there are risks associated with competition and financial performance.

Positives

• DANYELZA sales showed strong growth internationally, with a 55% increase in revenue.
• The company successfully launched DANYELZA in new markets, including Brazil and Mexico.
• DANYELZA received marketing authorization in Hong Kong, expanding its global reach.
• The company's cash burn was lower than expected in the first half of 2024, at $0.8 million.
• The company has a strong cash position of $77.8 million, expected to support operations into 2027.
• Gross margins improved due to a favorable gross profit mix from lower vial volumes from international regions.
• The company is on track to complete Part A of its GD2-SADA Phase 1 clinical trial in the fourth quarter of 2024.
• The company has appointed a new CFO and Chief Development Officer, strengthening its leadership team.

Negatives

• U.S. DANYELZA revenues decreased by 4% due to competition and ongoing clinical trials.
• The company reported a net loss of $9.2 million for the quarter and $15.9 million for the first six months of 2024.
• Selling, general, and administrative expenses increased significantly due to legal settlements.
• Interest and other income decreased due to foreign currency transaction losses and the absence of a secured promissory note repayment.

Risks

• The company faces competition in the U.S. market, which has impacted DANYELZA sales.
• The company's financial results were negatively impacted by legal settlements.
• The company's future performance is subject to various risks, including those related to clinical trials, regulatory approvals, and market acceptance of its products.
• The company's cash runway estimate is based on assumptions that may prove to be inaccurate.
• The company is exposed to risks related to macroeconomic conditions, including inflation and uncertain global credit markets.

Future Outlook

The company anticipates its current cash runway will support operations into 2027, and expects to complete Part A of its GD2-SADA Phase 1 clinical trial in the fourth quarter of 2024. Full year 2024 total net revenue guidance is between $87 million and $95 million.

Management Comments

• We demonstrated commercial progress with DANYELZA in the second quarter of this year while continuing to advance our development pipeline, said Mike Rossi, President and Chief Executive Officer.
• Our dedicated U.S. sales team with deep neuroblastoma expertise continues to penetrate new centers with DANYELZA, a leading anti-GD2 therapy, added to two more hospital formularies in the second quarter of 2024, while our ex-U.S. distribution partners have gained traction in our Eastern Asia and Latin America markets.
• Looking ahead, we are on track to complete Part A of our GD2-SADA Phase 1 clinical trial in the fourth quarter of this year with a data readout to follow and are on track to dose the first patient in our CD38-SADA Phase 1 in Non-Hodgkins Lymphoma trial in the second half of this year.

Industry Context

The report highlights Y-mAbs' efforts to expand its market presence for DANYELZA, a therapy for neuroblastoma, in a competitive landscape. The company's focus on international markets and the development of its SADA-PRIT technology platform positions it to compete in the evolving field of cancer therapeutics.

Comparison to Industry Standards

• Y-mAbs' 10% revenue growth for DANYELZA in Q2 2024 is a positive sign, but the 4% decline in U.S. revenue indicates challenges in the domestic market, possibly due to competition from other therapies such as those from United Therapeutics or Jazz Pharmaceuticals.
• The company's international expansion, particularly in Latin America, is a strategic move similar to other biopharmaceutical companies seeking growth outside of the U.S. market, such as Amgen or Biogen.
• The cash burn of $0.8 million for the first half of 2024 is relatively low compared to other companies in the clinical stage, such as those developing novel therapies like CRISPR Therapeutics or Editas Medicine, which often have higher cash burn rates due to extensive R&D activities.
• The company's focus on radioimmunotherapy and the SADA-PRIT platform is a unique approach, differentiating it from companies focused on traditional antibody therapies, such as Regeneron or Genmab.

Management Changes

Legal Proceedings

• The company settled a shareholder class-action lawsuit, resulting in a net charge of $3.8 million.

Stakeholder Impact

• Shareholders may be concerned about the net loss and the decrease in U.S. revenue, but encouraged by the international growth and the company's cash runway.
• Employees may be impacted by the company's financial performance and strategic shifts.
• Customers (hospitals and patients) will benefit from the expanded availability of DANYELZA.
• Suppliers may see increased demand for DANYELZA production.
• Creditors will be interested in the company's cash position and ability to meet its obligations.

Next Steps

• The company will complete Part A of the Phase 1 GD2-SADA Trial in the fourth quarter of 2024.
• The company will dose the first patient in the CD38-SADA Phase 1 trial in Non-Hodgkins Lymphoma in the second half of 2024.
• The company will continue to expand the commercial reach of DANYELZA in international markets.
• The company will host a conference call on August 12, 2024, to discuss the results.

Key Dates

Keywords

DANYELZA, Y-mAbs, Neuroblastoma, Radioimmunotherapy, SADA-PRIT, Naxitamab, Cancer Therapy, Biopharmaceutical, Financial Results, Clinical Trials